the phase II study of chemotherapy with Docetaxel+Nedaplatin+5-FU(DNF) to esophageal cancer
- Conditions
- StageII,III,IV non-resective esophageal cancer and recurrece ofesophageal cancer
- Registration Number
- JPRN-UMIN000005081
- Lead Sponsor
- Gunma University Graduate School Department of General Surgical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1.It is the patient having an anaphylactic history for DOC, CDGP, 5-FU and polysorbate "80" component pharmaceutical. 2.Severe complicate disease (malignant hypertension, severe heart failure, liver failure, liver cirrhosis, diabetes mellitus under inadequate control, bleeding disorders) 3.Infectious disease with fever up 4.Regardless of presence of a cause, it is motor paralysis, the patient having peripheral neuropathy, severe edema 5.pleural effusion or cardiac effusion need to treatment. 6.The patient having active multiple primary cancer. 7.During the pregnancy or a pregnant female patient we are possible or are nursing. 8.The patient having the interstitial pneumonia that is apparent by chest X-rays or CT or pulmonary fibrosis 9.The patient whom we merge psychosis or neurologic manifestation, and it is judged to have difficulty with participation to an examination. 10.the case that resarch contact doctor regards as inadequate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy
- Secondary Outcome Measures
Name Time Method overall survival time, safety, efficacy, progression free survival time